Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with ... | News | bakersfield.com

Feb 27, 2025

AUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, having determined an RP2D.

The ReSPECT-LM single-dose escalation trial assessed the safety, tolerability, and potential efficacy of intrathecally administered Rhenium (186Re) Obisbemeda in patients with leptomeningeal metastases (LM). Enrollment in Cohort 6 was recently completed (75.0 mCi). The Cohort 4 dose (44.1 mCi) was determined to be the RP2D; no dose-limiting toxicities were observed at this dose level. One patient at the Cohort 4 dose was observed to have achieved a complete response, as evidenced by the eradication of tumor cells in the cerebrospinal fluid—a key therapeutic endpoint.

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Please enable it in your browser settings.

Previous: New sustainable supply chain approach for tantalum implants by Croom Medical and GAM - 3D Printing Industry Next: Greenland Resources Secures Major Off-Take Agreement with Outokumpu for Molybdenum

Send inquiry

Send